Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer

Brönimann S., Pradere B., Karakiewicz P., Abufaraj M., Briganti A., Shariat Sh.
Expert Review of Molecular Diagnostics
Vol.20, Issue8, P. 841-850
Опубликовано: 2020
Тип ресурса: Обзор

DOI:10.1080/14737159.2020.1785288

Аннотация:
Introduction: This manuscript aims to give an overview of current diagnostic, staging, and prognostic markers for prostate cancer (PCa) and discuss emerging approaches. The widespread use of PSA for early detection led to improved survival but at the cost of over-diagnosis, often associated with over-treatment and its adverse events. There is thus an unmet need for new markers to sustainably improve the diagnosis and risk assessment, thereby providing a more accurate treatment decision for each individual patient. Areas covered: Promising new molecular serum (PSA, PHI, 4Kscore®), urine (Progensa®, SelectMDx®, MiPS) and tissue-based markers (Ki-67, Prolaris®, ConfirmMDx®, Oncotype Dx®, Decipher®, Promark®) will be discussed in this review. Expert opinion: Over-diagnosis and difficulties in prognosticating clinical outcome among patients with similar histological and clinical parameters often lead to over- or under-treatment. New markers will probably be used with clinical and histopatho
Ключевые слова:
Diagnosis; molecular marker; prognosis; prostate cancer
Язык текста: Английский
ISSN: 1744-8352
Brönimann S.
Pradere B.
Karakiewicz P.
Abufaraj M.
Briganti A.
Shariat Sh. Sharokh 1973-
Брöниманн С.
Прадере Б.
Каракиеwиcз П.
Абуфарай М.
Бриганти А.
Шариат Ш. Шарох 1973-
An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer
Текст визуальный непосредственный
Expert Review of Molecular Diagnostics
Future Drugs Ltd.
Vol.20, Issue8 P. 841-850
2020
Обзор
Diagnosis molecular marker prognosis prostate cancer
Introduction: This manuscript aims to give an overview of current diagnostic, staging, and prognostic markers for prostate cancer (PCa) and discuss emerging approaches. The widespread use of PSA for early detection led to improved survival but at the cost of over-diagnosis, often associated with over-treatment and its adverse events. There is thus an unmet need for new markers to sustainably improve the diagnosis and risk assessment, thereby providing a more accurate treatment decision for each individual patient. Areas covered: Promising new molecular serum (PSA, PHI, 4Kscore®), urine (Progensa®, SelectMDx®, MiPS) and tissue-based markers (Ki-67, Prolaris®, ConfirmMDx®, Oncotype Dx®, Decipher®, Promark®) will be discussed in this review. Expert opinion: Over-diagnosis and difficulties in prognosticating clinical outcome among patients with similar histological and clinical parameters often lead to over- or under-treatment. New markers will probably be used with clinical and histopatho